ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

alpha 1-Antitrypsin

Also written as “Alpha-1 MP”, “GLASSIA” and “Alpha1-proteinase inhibitor”.

Its studies are mostly in alpha 1-Antitrypsin Deficiency · Pulmonary Disease, Chronic Obstructive · Pulmonary Emphysema · Graft vs Host Disease · Diabetes Mellitus, Type 1, led by 4 companies.

Drug pageAlpha 1-Antitrypsin: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 20, 200626 company-led studies, 2 open or runningNext primary completion: Sep 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grifols131 open or runningphase 3since Feb 20, 2006Sep 12, 2005Sep 2028phase 3 · NCT02796937
Takedaits history only70 open or runningphase 4since Nov 3, 2006Nov 3, 2006none ahead
CSLits history only31 open or runningphase 4since Dec 2, 2005Dec 2, 2005Sep 15, 2033phase 4 · NCT07326592
Kamadaits history only30 open or runningphase 3since Dec 17, 2019Feb 24, 2011none ahead

Also a collaborator on its studies: Baxalta Innovations GmbH, now part of Shire.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Grifols only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2005First study: phase 2 study in alpha 1-Antitrypsin DeficiencyFirst studyNCT00263887 · 77 enrolled · Denmark, Sweden, United Kingdom
  2. Feb 20, 2006Phase 3 study in alpha 1-Antitrypsin DeficiencyNCT00295061 · 24 enrolled · United States
  3. Mar 8, 2006Phase 3 study in alpha 1-Antitrypsin DeficiencyNCT00301366 · 38 enrolled · United States, United Kingdom
  4. Jun 13, 2007Phase 2 study in Cystic FibrosisNCT00486837 · 72 enrolled
  5. Sep 29, 2010Phase 2 study in EmphysemaNCT01213043 · 30 enrolled · United States
  6. Sep 6, 2012Phase 2 study in Cystic FibrosisNCT01684410 · 30 enrolled · United States
  7. Oct 28, 2013Phase 3 study in Pulmonary EmphysemaNCT01983241 · 345 enrolled · United States, Argentina, Australia and more
  8. Mar 11, 2014Phase 2 study in Diabetes Mellitus, Type 1NCT02093221 · 76 enrolled · United States
  9. Oct 31, 2014Phase 3 study in Alpha₁-Antitrypsin DeficiencyNCT02282527 · 32 enrolled · United States
  10. Jun 3, 2016Phase 3 study in Pulmonary EmphysemaNCT02796937 · 290 planned · United States, Australia, Canada and more
  11. Aug 12, 20162 phase 2 studies in alpha 1-Antitrypsin DeficiencyNCT02870348, NCT02870309
  12. Jul 28, 2020Phase 2 study in COVID-19NCT04495101 · 100 enrolled · Spain

Ahead

  1. Sep 2028Primary completion: phase 3 study in Pulmonary EmphysemaNCT02796937

TargetBeta

ELANE →read by rule
“Leukocyte elastase inhibitor”ChEMBL 37, by rule

Studies

All 13 Grifols leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04495101COVID-19 · Spain2CompletedApr 26, 2021100
NCT02870348alpha 1-Antitrypsin Deficiency · Japan2CompletedFeb 16, 20214
NCT02870309alpha 1-Antitrypsin Deficiency · Japan2CompletedMar 15, 20174
NCT02796937Pulmonary Emphysema · United States, Australia, Canada and more3By invitationSep 2028290
NCT02282527Alpha₁-Antitrypsin Deficiency · United States3CompletedJan 201632
NCT02093221Diabetes Mellitus, Type 1 · United States2TerminatedJan 201776
NCT01983241Pulmonary Emphysema · United States, Argentina, Australia and more3CompletedJul 7, 2026345
NCT01684410Cystic Fibrosis · United States2CompletedOct 201330
NCT01213043Emphysema · United States2CompletedJan 201230
NCT00486837Cystic Fibrosis2CompletedJun 200472
NCT00301366alpha 1-Antitrypsin Deficiency · United States, United Kingdom3CompletedMar 200738
NCT00295061alpha 1-Antitrypsin Deficiency · United States3CompletedFeb 200724
NCT00263887alpha 1-Antitrypsin Deficiency · Denmark, Sweden, United Kingdom2CompletedJan 200777

How it is read

Names in the registry

  • “Alpha-1 MP”, 5 entries
  • “GLASSIA”, 2 entries
  • “Alpha1-proteinase inhibitor”, 2 entries
  • “Alpha1-Proteinase Inhibitor (Human)”, 2 entries
  • “CE1226”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.